Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am not worried about it at all. This valley ride was just what many needed in order to add more shares at such a ridiculously low PPS! This is most-likely the bottom. ~IMO
Sentiment may be the most classical of all.
Who said that it wasn't?
This is about an "ok" as you are going to get. ~IMO
Not in my book...
Should be plenty of room for both, and one can only speculate as to how much fuel is currently stored awaiting a permit to sell.
Kinda' like an inverse bear raid with the bears in the lead...
So that's where this is going then...?
It would seem that too much discussion is taking place around an alleged email posted by a new poster that has only had 2 posts on ihub.
http://investorshub.advfn.com/boards/ProfileA.aspx?user=207340
1.75's tasted good today - thanks to the seller!
Less serious than unsubstantiated materially false implications by the few.
If all of this hearsay is actually true, then this would be the most logical and realistic assumption:
Today would be nice.
I suspect that the foundation is being laid for every contingency known to man prior to the global launch.
Drivel...
Has your research concluded yet? What is your logical conclusion, and what is it based upon (exactly, please)?
All testing is complete...
Obviously, not enough research has be done here...
Permitting is the issue here my friend...
I thought we were debating Islechem being a independent startup of OxyChem...
...it was not as independent of a startup as one would incoherently presume. It was more of a spin-off, per say of a segment of their business that they no longer wished to participate in. Happens all the time to businesses - also considered to be "normal course of action" for involving companies.
Obviously, this is "what is so hard to understand?":
This was the beginning of IsleChem:
Friday, May 3, 2002
With OxyChem set to close tech center, IsleChem was born
Business First of Buffalo - by Tom Hartley Business First
Type of business: Contract chemical research and development, analysis, and manufacturing.
Who's who: Dr. Charles Rader, Dale Kunze and Edward Rowe are equal partners. Rader is chief executive officer of the company, Kunze is vice president of operations, and Rowe is vice president-commercial director of marketing, sales and tech services.
Clients/customers: Customers are mid- and large-size chemical companies, including Occidental Chemical Corp., which formerly owned the business.
Company history: Prior to last Nov. 30, IsleChem's founders were employed at Occidental's Grand Island technology center, now home of IsleChem.
Rader was a senior vice president in research and development, Kunze was technical director and Rowe was director of commercial development.
When OxyChem targeted the tech center for closing in a cost-cutting move, the three proposed keeping the business going by forming a new company and buying the building along with the expensive analytical and testing equipment.
At its peak, the tech center had 275 employees, but the number was only about 40 in 2001. The new company has 20 employees, all but one formerly with OxyChem.
IsleChem, which officially began operations last December, bought the 88,000-square-foot building and land for $375,000. The full value of the deal was undisclosed, but Rowe said the cost of replacing everything would exceed $30 million. This takes in the equipment in the approximately 20 fully-equipped laboratories, including seven that IsleChem uses, a pilot facility and the manufacturing area.
In addition to IsleChem, which uses about 25,000 square feet of space, the technology center houses three tenants: Durez Corp., which occupies about 11,000 square feet, and Process Technology Optimization Inc. and Programmable Life Inc., both of which use less space.
"We expect more tenants by July, which would mean that 40 percent of the building is occupied. Our target is to have 100 employees on this site by the end of the year," Rader said.
IsleChem's scope of work includes contract research and development, analytical services, sales and marketing in the United States for foreign companies, manufacturing of small-scale chemicals and scale-up work on ideas that start in a lab. "Some of what we do in R&D may end up in manufacturing eventually," Rowe says.
Revenues: Projected to reach $3 million by the end of this year, they are seen ranging upwards of $10 million by 2006.
What's ahead: The company expects to hire more employees this year and will double in size to 40 employees in two years. Kunze says employment could reach 50 by 2006, but there is no plan to be a large company with hundreds of employees on a scale of the tech center when OxyChem operated it.
Company strengths: "Our experienced people are our greatest strength," Rader says. "The average salary of our staff is $65,000 and that says something about our academic training."
Fifty percent of the employees in the knowledge-based organization have PHds in chemistry or chemical engineering.
The average experience is more than 20 years.
Down the road: In June, IsleChem and the University at Buffalo will launch a joint summer program.
The company will provide facilities, mentors and a stipend for students in UB's graduate chemical engineering program.
Initially, two students will be involved, but Rader envisions as many as 10 in a few years if the program is successful. They will work on real-world industrial problems submitted by IsleChem customers to earn six credit hours toward a masters degree.
"One of our overall goals in investing in this is to help keep a skilled work force in Western New York," Rader said.
The mission: Of several major key core areas, the two biggest are contract R&D and contract manufacturing.
Of the two, the manufacturing portion of the business is being developed to a higher level so it more evenly balances with R&D.
"Contract manufacturing is likely to be one of the most important aspects of our business," Kunze says.
The challenge: "We are going down a couple of avenues aggressively," Rader said. "One is we are launching our own line of chemicals which will be small-volume, high-value that we will market and sell.
"Secondly, we need to fully utilize the assets we have available for analytical work on site and expand our analytical services businesses," he said.
http://www.bizjournals.com/buffalo/stories/2002/05/06/smallb1.html
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=50766217 <--this one was to you btw...
Moves on air...
Shouldn't surprise any true believers, as it is predicted (somewhere) that once man recreates life, then the end is imminent.
And what do you base your opinion on?
I really see no problem in the "ability to keep them". Anyone in their right mind would see the incredible opportunity that exists with this company. ~IMO of course
Is this Déjà vu dude?
The "karma" here would be the reference to Moore Stephens.
Are we still discussing this one as well?
karma
Follow the thread dude/tte.
Are we still on this?
I really don't see where that would make any difference to a non-shareholder. What do you think?
The one that is currently associated with the ticker symbol JBIIE.
Yes, we are indeed scraping here:
What does that have to do with JBI, Inc. imminent business roll-out?
lol - should put that one to rest, but probably not.
Believe me, it exists here.
I cannot show you that!
Damn! Its only Monday, and we already have the post of the week!